Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 32Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm Metastasis 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Burkitt Lymphoma 2Thromboembolism 1Sarcoma 1Prostate Adenocarcinoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia 1Kidney Neoplasms 1Hodgkin Disease 1Fibrosarcoma 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

niraparib 1Watchful Waiting 1Surveys and Questionnaires 1Receptors, Bombesin 1Radiotherapy 1Radiosurgery 1Radiation Dose Hypofractionation 1Radiation 1Observation 1Neoadjuvant Therapy 1Magnetic Resonance Spectroscopy 1Gallium 1Estramustine 1Docetaxel 1Diet Therapy 1Cholecalciferol 1Carboplatin 1BAY 86-7548 1Adjuvants, Pharmaceutic 168Ga-bombesin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Prostate Adenocarcinoma × Estramustine × Clear all
NCT00183924 2014-05-22

Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy.

University of Southern California

Phase 2 Completed
20 enrolled
Genitourinary

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡